CS
NWBO

Credit Suisse’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Credit Suisse’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,898,904
Closed -$1.03M – 4389
2016
Q3 		$1.03M Sell
1,898,904
-237,078
-11% -$108K ﹤0.01% 2932
2016
Q2 		$1.24M Buy
2,135,982
+195,142
+10% +$208K ﹤0.01% 2743
2016
Q1 		$2.83M Sell
1,940,840
-42,842
-2% -$84.5K ﹤0.01% 1944
2015
Q4 		$6.35M Sell
1,983,682
-791,559
-29% -$3.81M 0.01% 1417
2015
Q3 		$17.3M Buy
2,775,241
+1,838,336
+196% +$17.2M 0.02% 826
2015
Q2 		$9.3M Buy
+936,905
New +$8.21M 0.01% 1295
2015
Q1 		– Sell
-18,876
Closed -$101K – 4847
2014
Q4 		$101K Buy
+18,876
New +$96.6K ﹤0.01% 4434
2014
Q2 		– Sell
-182,349
Closed -$1.32M – 5026
2014
Q1 		$1.32M Sell
182,349
-152,316
-46% -$903K ﹤0.01% 2868
2013
Q4 		$1.26M Buy
334,665
+60,349
+22% +$234K ﹤0.01% 3083
2013
Q3 		$922K Buy
274,316
+31,188
+13% +$109K ﹤0.01% 3029
2013
Q2 		$812K Buy
+243,128
New +$881K ﹤0.01% 2957

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Credit Suisse's NWBO Position: Q4 2016 in Review

Credit Suisse sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 1,898,904 shares — an estimated $1.03M sold.

Credit Suisse first reported a position in NWBO in Q2 2013 and held it in 11 quarters. The position peaked at $17.3M in Q3 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Credit Suisse reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Credit Suisse sold 1,898,904 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $1.03M.
  • Credit Suisse first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 11 quarters.
  • Credit Suisse's Northwest Biotherapeutics, Inc. Common stock position peaked at $17.3M in Q3 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Credit Suisse's 13F filing for Q4 2016, filed 14 Feb 2017.